Dr. Jeffrey R. Jay, M.D.
Latest statistics and disclosures from Great Point Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ALPN, CYTK, URGN, PLRX, RARE, and represent 36.75% of Great Point Partners's stock portfolio.
- Added to shares of these 10 stocks: Neurogene (+$19M), Tourmaline Bio (+$18M), Abivax SA F (+$17M), ALPN (+$12M), ARVN (+$9.6M), VTGN (+$9.6M), FOLD (+$6.0M), PBYI, XENE, TERN.
- Started 11 new stock positions in MRUS, PBYI, ARVN, Mural Oncology, Abivax SA F, Tourmaline Bio, Neurogene, AXSM, VTGN, OCUL. SYRE.
- Reduced shares in these 10 stocks: Point Biopharma Global (-$19M), SRPT (-$17M), ACRS (-$16M), ACLX (-$13M), PTCT (-$11M), REPL (-$11M), PCVX (-$11M), AKRO (-$10M), KRTX (-$9.6M), RAPT (-$8.9M).
- Sold out of its positions in ACRS, ABOS, AKRO, Ambrx Biopharma, CERE, GBIO, GOSS, GRCL, HRTX, IGMS. MRTX, PTCT, Point Biopharma Global, RPHM, REPL, SLDB, Talaris Therapeutics.
- Great Point Partners was a net seller of stock by $-90M.
- Great Point Partners has $587M in assets under management (AUM), dropping by 6.86%.
- Central Index Key (CIK): 0001281446
Tip: Access up to 7 years of quarterly data
Positions held by Dr. Jeffrey R. Jay, M.D. consolidated in one spreadsheet with up to 7 years of data
Download as csv Download as ExcelPortfolio Holdings for Great Point Partners
Great Point Partners holds 34 positions in its portfolio as reported in the December 2023 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Alpine Immune Sciences (ALPN) | 12.0 | $71M | +20% | 3.7M | 19.06 |
|
Cytokinetics Com New (CYTK) | 7.1 | $42M | -16% | 500k | 83.49 |
|
Urogen Pharma (URGN) | 6.7 | $39M | 2.6M | 15.00 |
|
|
Pliant Therapeutics (PLRX) | 5.6 | $33M | +3% | 1.8M | 18.11 |
|
Ultragenyx Pharmaceutical (RARE) | 5.3 | $31M | -10% | 648k | 47.82 |
|
Xenon Pharmaceuticals (XENE) | 4.7 | $28M | +19% | 600k | 46.06 |
|
Rapt Therapeutics (RAPT) | 4.7 | $27M | -24% | 1.1M | 24.85 |
|
Alkermes SHS (ALKS) | 4.1 | $24M | 875k | 27.74 |
|
|
Aerovate Therapeutics (AVTE) | 4.0 | $24M | -4% | 1.0M | 22.63 |
|
Vaxcyte (PCVX) | 3.9 | $23M | -32% | 360k | 62.80 |
|
Evolus (EOLS) | 3.6 | $21M | -8% | 2.0M | 10.53 |
|
Anaptysbio Inc Common (ANAB) | 3.6 | $21M | +9% | 977k | 21.42 |
|
Immunocore Hldgs Ads (IMCR) | 3.4 | $20M | 293k | 68.32 |
|
|
Neurogene | 3.3 | $19M | NEW | 994k | 19.38 |
|
Amicus Therapeutics (FOLD) | 3.1 | $18M | +49% | 1.3M | 14.19 |
|
Tourmaline Bio | 3.0 | $18M | NEW | 673k | 26.18 |
|
Abivax Sa Sponsored Ads | 2.8 | $17M | NEW | 1.6M | 10.70 |
|
Zura Bio Class A Ord Shs (ZURA) | 2.6 | $15M | 3.3M | 4.67 |
|
|
Optinose (OPTN) | 1.9 | $11M | 8.8M | 1.29 |
|
|
Apogee Therapeutics (APGE) | 1.9 | $11M | 400k | 27.94 |
|
|
Arvinas Ord (ARVN) | 1.6 | $9.6M | NEW | 234k | 41.16 |
|
Karuna Therapeutics Ord (KRTX) | 1.6 | $9.6M | -50% | 30k | 316.51 |
|
Vistagen Therapeutics Ord (VTGN) | 1.6 | $9.6M | NEW | 1.9M | 5.14 |
|
Terns Pharmaceuticals (TERN) | 1.4 | $8.5M | +102% | 1.3M | 6.49 |
|
Intra Cellular Therapies (ITCI) | 1.4 | $7.9M | -50% | 111k | 71.62 |
|
Sarepta Therapeutics (SRPT) | 1.3 | $7.7M | -69% | 80k | 96.43 |
|
Insmed Com Par $.01 (INSM) | 1.2 | $7.0M | -42% | 226k | 30.99 |
|
Puma Biotechnology (PBYI) | 0.8 | $4.7M | NEW | 1.1M | 4.33 |
|
Ocular Therapeutix (OCUL) | 0.5 | $3.1M | NEW | 700k | 4.46 |
|
Spyre Therapeutics Com New (SYRE) | 0.5 | $2.7M | NEW | 125k | 21.52 |
|
Arcellx Common Stock (ACLX) | 0.5 | $2.7M | -83% | 48k | 55.50 |
|
Merus N V (MRUS) | 0.1 | $550k | NEW | 20k | 27.50 |
|
Axsome Therapeutics (AXSM) | 0.1 | $395k | NEW | 5.0k | 79.59 |
|
Mural Oncology Pub Ord Shs | 0.0 | $68k | NEW | 12k | 5.92 |
|
Past Filings by Great Point Partners
SEC 13F filings are viewable for Great Point Partners going back to 2013
- Great Point Partners 2023 Q4 filed Feb. 14, 2024
- Great Point Partners 2023 Q3 filed Nov. 14, 2023
- Great Point Partners 2023 Q2 filed Aug. 14, 2023
- Great Point Partners 2023 Q1 filed May 15, 2023
- Great Point Partners 2022 Q4 filed Feb. 14, 2023
- Great Point Partners 2022 Q3 filed Nov. 14, 2022
- Great Point Partners 2022 Q2 filed Aug. 15, 2022
- Great Point Partners 2022 Q1 filed May 16, 2022
- Great Point Partners 2021 Q4 filed Feb. 14, 2022
- Great Point Partners 2021 Q3 filed Nov. 15, 2021
- Great Point Partners 2021 Q2 filed Aug. 16, 2021
- Great Point Partners 2021 Q1 filed May 17, 2021
- Great Point Partners 2020 Q4 filed Feb. 16, 2021
- Great Point Partners 2020 Q3 filed Nov. 16, 2020
- Great Point Partners 2020 Q2 filed Aug. 14, 2020
- Great Point Partners 2020 Q1 filed May 15, 2020